ASCO2021: Patritumab Deruxtecan produces durable response in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer patients

The results of a phase I dose escalation and dose expansion study (U31402-A-U102,) showed that Patritumab deruxtecan has a long-lasting effect in patients with non-small cell lung cancer , regardless of the EGFR tyrosine kinase inhibitor resistance mechanism
.

Patritumab deruxtecan has a long-lasting effect in patients with non-small cell lung cancer Patritumab deruxtecan has a long-lasting effect in patients with non-small cell lung cancer

Effective treatment of patients with EGFR inhibitor resistance and EGFR mutation (EGFRm) non-small cell lung cancer ( NSCLC ) is hindered by the development of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in standard care
.

In a report at the ASCO annual meeting in 2021, Pasi A.

NSCLC ASCO

HER3-DXd is a human anti-HER3 IgG1 monoclonal antibody for clinical evaluation of NSCLC, metastatic breast cancer and colorectal cancer
.

HER3 is expressed in the vast majority of non-small cell lung cancers.

Breast cancer and colorectal cancer

Patritumab Deruxtecan activity and patient's previous treatment results

Patritumab Deruxtecan activity and patient's previous treatment results

The study included 57 patients with EGFR TKI resistance, EGFRm NSCLC patients using 5.
6 mg/kg HER3-DXd for dose escalation (12 cases) and dose expansion cohort 1 (45 cases)
.

All patients have received a lot of preoperative treatment, and all patients have received EGFR TKI treatment before, most of them have also received platinum chemotherapy before, and the median has received four systemic treatments before

The efficacy of
HER3-DXd is high in a large number of pretreated patients, with a response rate of 39% and a progression-free survival of 8.

2 months .

The efficacy of

Regardless of previous treatment or history of brain metastases, persistent responses were observed

21% receiving 5.

The curative effect is clinically significant and has a long-lasting effect, the effective rate is 39%, and the median progression-free survival is 18.

The effectiveness of HER3-DXd in all reported resistance mechanisms EGFR-related total remission rate is 47%, and the total remission rate of non-EGFR, MET-related patients is 45%.
HER3-DXd is among all reported resistance mechanisms the effectiveness of EGFR-related overall response rate of 47% instead of EGFR, MET overall response rate in patients with associated 45% immunity in this message